NATIMMUNE A/S
NatImmune A/S operates a biotech company focusing on the development of protein-based therapeutics.
Similar Organizations
Actigen Ltd
Actigen Ltd is an biotechnology company engaged in the development of human antibody therapeutics.
Baliopharm
Baliopharm AG is a biotechnology company focusing on the development of novel therapeutics.
More informations about "NatImmune A/S"
NatImmune 2025 Company Profile: Valuation, Investors
NatImmune Acquisitions (2) NatImmune’s most recent deal was a Merger/Acquisition with Nya Hamlet Pharma. The deal was made on 18-Sep-2006. Company Name Deal Date Deal Type …See details»
NatImmune A/S - Crunchbase Company Profile & Funding
Organization. NatImmune A/S . Connect to CRM . Save . Summary. People. Signals & News. Similar Companies. About. NatImmune A/S operates a biotech company focusing on the …See details»
NatImmune A/S - LinkedIn
NatImmune A/S | 69 followers on LinkedIn. ... AM Group Business Consulting and Services Hillerød, Capital Region of DenmarkSee details»
NatImmune - 2025 Company Profile, Funding & Competitors
Mar 28, 2025 NatImmune - Developer of protein therapeutics for oncology and infectious diseases. Raised funding from 1 investor. NatImmune has 336 competitors.See details»
NatImmune - Products, Competitors, Financials, Employees, …
NatImmune A/S has developed a product for replacement therapy of Mannan Binding Lectin (MBL) in patients carrying genetic pre-disposition to infections through a deficiency in the …See details»
Organization | NatImmune A/S
NatImmune A/S Report issue. For profit Phase 2. Founded: Copenhagen Denmark ... Organization Overview. First Clinical Trial. 2008 NCT00644579. First Marketed Drug. None …See details»
NatImmune A/S - M&A Summary and Business Overview - Mergr
Sep 7, 2006 NatImmune A/S was founded in 2000. M&A Summary. M&A Total Activity1. M&A Buy Activity1; Total Sectors Invested 1; Total Countries Invested 1; NatImmune A/S. Symbion …See details»
Natimmune - Overview, News & Competitors | ZoomInfo.com
The products in NatImmune's pipeline address strong medical needs and significant market opportunities. The market potential for rhMBL for supportive care in immunosuppressed …See details»
Natimmune A/S - BioCentury Company Profiles - BCIQ
Feb 16, 2009 Natimmune A/S - BioCentury Company Profiles for the biopharma industrySee details»
BAMLET(NatImmune A/S) - Drug Targets, Indications, Patents
May 7, 2025 BAMLET(NatImmune A/S), Initially developed by Azanta Danmark AS, Now, its global highest R&D status is Pending, Therapeutic Areas: Neoplasms,Urogenital Diseases. ...See details»
NatImmune - Radcliffe Cardiology
NatImmune. Location. Symbion Science Park Fruebjergvej 3,Box 3. Copenhagen. Email Address [email protected]. Phone +45 70 22 35 60. Fax +45 70 22 35 80. Website ... (s) and not of …See details»
Company Information - RocketReach
NatImmune A/S Management NatImmune A/S employs 5 employees. Get Contact Info for All Departments Looking for a particular NatImmune A/S employee's phone or email? Find Info …See details»
BAMLET(NatImmune A/S) - Drug Targets, Indications, Patents
Apr 2, 2024 BAMLET(NatImmune A/S), Initially developed by Azanta Danmark A/S, Now, its global highest R&D status is Pending, Therapeutic Areas: Neoplasms,Urogenital Diseases. …See details»
NatImmune Stock Price, Funding, Valuation, Revenue ... - CB Insights
See NatImmune funding rounds, investors, investments, exits and more. Evaluate their financials based on NatImmune's post-money valuation and revenue. NatImmune Stock Price, Funding, …See details»
NatImmune A/S - Party | RPX Insight
NatImmune A/S has 0 patent litigation cases (0 cases currently active) - 0 patents asserted - 0 cases as a plaintiff - 0 cases as a defendant ... View as Organization NatImmune A/S Related …See details»
NatImmune A/S - Crunchbase
NatImmune A/S operates a biotech company focusing on the development of protein-based therapeutics. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. …See details»
Patents Assigned to Natimmune A/S - Justia Patents Search
Assignee: Natimmune A/S Inventor: Per Fischer Isolation of lectins. Patent number: 7049414 Abstract: The invention relates to a process for isolating a lectin composition, in particular …See details»
Recombinant human mannose-binding lectin(NatImmune A/S)
Quantum dots (QDs) have stood out as nanotools for glycobiology due to their photostability and ability to be combined with lectins. Mannose-binding lectin (MBL) is involved in the innate …See details»
Recombinant human mannose-binding lectin - NatImmune/Enzon
Alternative Names: rhMBL; rhMBL - NatImmune/Enzon Latest Information Update: 29 Dec 2021 Price : $50 * Buy Profile. Note: Adis is an information provider. We do not sell or distribute …See details»
NatImmune, Enzon Enter Deal On Recombinant MBL - BioWorld
Oct 5, 2005 NatImmune A/S licensed its lead project, recombinant human mannan-binding lectin (rhMBL), in development for prevention of severe infection in MBL-deficient individuals …See details»